Successful T cell engineering with gene scissors
The idea of genetically modifying a patient’s own immune cells and deploying them against infections and tumors has been around since the 1980s. But to this day modified T cells are still not as effective as natural T cells and have been only been of limited clinical value. Using the new CRISPR-Cas9 gene editing tool, a team at the Technical University of Munich (TUM) has now engineered T cells that are very similar to physiological immune cells.
There are two forms of T cell therapy: either a recipient receives cells from a donor, or the recipient’s own T cells are removed, genetically reprogrammed in a laboratory and unleashed against an infection or tumor in the body. While the first method has proven to be successful in clinical models, reprogramming T cells is still beset with problems.
The team led by Professor Dirk Busch, Director of the Institute for Medical Microbiology, Immunology and Hygiene at the TUM, has generated modified T cells for the first time that are very similar to their natural counterparts and could solve some of those problems. To do so, they utilized the new CRISPR-Cas9 gene scissors, which can be used to snip out and replace targeted segments of the genome.
Both the conventional methods and the new method target the key homing instrument of T cells, known as the T cell receptor. The receptor, residing on the cell’s surface, recognizes specific antigens associated with pathogens or tumor cells, which the T cell is then able to attack. Each receptor is made up of two molecular chains that are linked together. The genetic information for the chains can be genetically modified to produce new receptors that are able to recognize any desired antigen. In this way, it is possible to reprogram T cells.
Targeted exchange using the CRISPR-Cas9 gene scissors
The problem with conventional methods is that the genetic information for the new receptors is randomly inserted into the genome. This means that T cells are produced with both new and old receptors or with receptors having one old and one new chain. As a result, the cells do not function as effectively as physiological T cells and are also controlled differently. Moreover, there is a danger that the mixed chains could trigger dangerous side effects (Graft-versus-Host Disease, GvHD).
“Using the CRISPR method, we’ve been able to completely replace the natural receptors with new ones, because we’re able to insert them into the very same location in the genome. In addition, we’ve replaced the information for both chains so that there are no longer any mixed receptors,” explains Kilian Schober, who is a lead author of the new study along with his colleague Thomas Müller.
Near-natural properties
Thomas Müller explains the advantages of the modified T cells: “They’re much more similar to physiological T cells, yet they can be changed flexibly. They’re controlled like physiological cells and have the same structure, but are capable of being genetically modified.“ The scientists have demonstrated in a cell culture model that T cells modified in this way behave nearly exactly like their natural counterparts.
“Another advantage is that the new method allows multiple T cells to be modified simultaneously so that they’re able to recognize different targets and can be used in combination. This is especially interesting for cancer therapy, because tumors are highly heterogeneous,” Dirk Busch adds. In the future, the team plans to investigate the new cells and their properties in preclinical mouse models, an important step in preparing for clinical trials with humans.
Learn more: Successful T cell engineering with gene scissors
The Latest on: CRISPR-Cas9 gene scissors
[google_news title=”” keyword=”CRISPR-Cas9 gene scissors” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: CRISPR-Cas9 gene scissors
- Buy Rating on Crispr Therapeutics AG Backed by Exa-cel’s Precision and Favorable Safety Profileon April 25, 2024 at 11:24 pm
Salim Syed, an analyst from Mizuho Securities, maintained the Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The ...
- This AI Just Designed a More Precise CRISPR Gene Editor for Human Cells From Scratchon April 25, 2024 at 1:25 pm
Based on large language models—the tech behind the popular ChatGPT—Profluent's AI designed a new gene editor and put it to work in human cells.
- Cichlid fishes' curiosity promotes biodiversity: How exploratory behavior aids in ecological adaptationon April 25, 2024 at 11:00 am
Cichlid fishes exhibit differing degrees of curiosity. The cause for this lies in their genes, as reported by researchers from the University of Basel in the journal Science. This trait influences the ...
- What could EU changes around genetically modified crops mean for Ireland?on April 25, 2024 at 8:11 am
New legislation will allow for the increased use of new genomic techniques in plant research and crop development ...
- Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaborationon April 25, 2024 at 8:00 am
Regeneron Pharmaceuticals will use Mammoth Biosciences’ CRISPR-based ultracompact gene editing platform to develop in vivo therapies for tissues and cell types beyond the liver.
- Peninsula biotech co-founded by Jennifer Doudna lands CRISPR gene-editing pact with Regeneronon April 25, 2024 at 6:27 am
The big deal between Regeneron and a Peninsula biotech co-founded by Jennifer Doudna is also a small deal. And that’s a huge deal.
- OpenCRISPR-1: World’s first open-source AI scissor edits human geneson April 25, 2024 at 5:51 am
E very day brings with it a new achievement to the credit of AI. From creating full-length movies to predicting human actions, there is truly no domain left untouched by AI, including medicine and ...
- Enhanced CRISPR method enables stable insertion of large genes into the DNA of higher plantson April 24, 2024 at 8:46 am
Scientists at the Leibniz Institute of Plant Biochemistry (IPB) have succeeded for the first time in stably and precisely inserting large gene segments into the DNA of higher plants very efficiently.
- Profluent combines LLMs and CRISPR for open-source AI gene editing projecton April 23, 2024 at 11:00 am
Profluent has staked a claim at the intersection of some of the buzziest terms in biopharma. | Profluent has staked a claim at the intersection of some of the buzziest terms in biopharma. The protein ...
- Profluent Successfully Edits Human Genome with OpenCRISPR-1, the World’s First AI-Created and Open-Source Gene Editoron April 22, 2024 at 9:30 am
With this launch, Profluent demonstrates the first successful precision editing of the human genome with customizable gene editors designed from scratch with AI. OpenCRISPR-1 is an AI-created gene ...
via Bing News